Antibiotics Explained: Prokaryotic vs Eukaryotic Targets | Microbiology Basics

Added:

Mitochondrial Toxicity and the Limits of Selective Toxicity

While introductory microbiology emphasizes the neat division between prokaryotic and eukaryotic drug targets, this framework overlooks the evolutionary origin of eukaryotic organelles. According to the endosymbiotic theory, mitochondria evolved from engulfed aerobic bacteria and still retain prokaryotic characteristics, including circular DNA and 70S ribosomes. Consequently, several major classes of antibiotics—such as tetracyclines, aminoglycosides, and linezolid—can inadvertently target and disrupt host mitochondrial function. This mitochondrial cross-reactivity challenges the absolute dichotomy of 'prokaryotic-specific' targeting, explaining key clinical side effects and highlighting the limitations of selective toxicity in antibiotic design.

Fundamental structural differences between prokaryotic cells (bacteria) and eukaryotic cells (animals/humans).
The basic structure of the bacterial cell wall, specifically the composition and role of peptidoglycan.
The process of protein translation and the structural differences between prokaryotic (70S) and eukaryotic (80S) ribosomes.
An introductory understanding of DNA replication and transcription, including the role of key enzymes like DNA gyrase.
The concept of 'selective toxicity'—the ability of a drug to target a microbe without harming the host organism.
Mechanisms of bacterial resistance, such as target modification, enzymatic degradation (e.g., beta-lactamases), and drug efflux pumps.
Classification of major antibiotic families (such as beta-lactams, aminoglycosides, and fluoroquinolones) and their clinical applications.
The cellular basis of antibiotic side effects in humans, such as why targeting bacterial ribosomes can sometimes affect human mitochondria.
The biological challenges of developing selective therapies for eukaryotic pathogens (like fungi and protozoa) and viruses.
Practical pharmacology concepts including Minimum Inhibitory Concentration (MIC) and the distinction between bactericidal and bacteriostatic agents.
16.3K views233likes10:09@katharinabrandl361Original Release: 2015-05-21

Antibiotics selectively target bacteria by exploiting structural and metabolic differences between prokaryotic and eukaryotic cells, including cell wall synthesis (beta-lactams, glycopeptides), ribosome function (tetracycline, macrolides), nucleotide synthesis (sulfonamides, trimethoprim), and DNA replication (quinolones), with Gram-positive bacteria having thick peptidoglycan layers and Gram-negative bacteria possessing an outer membrane that limits antibiotic penetration.